Spexis sells antibiotics programme to Basilea
Spexis AG (Alschwil) has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd. Under the agreement Basilea will acquire a...
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
The acquisition will give Genmab access to ProfoundBio's portfolio of antibody-drug conjugates (ADCs), three of which are in clinical trials. The...
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
In a significant development in the biosolutions sector, Novozymes A/S and Chr. Hansen Holding A/S successfully completed their merger, forming a new...
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...